Novo Nordisk: disappointing results and outlook

(CercleFinance.com) - Novo Nordisk, the world's leading diabetes treatment company, has reported lower-than-expected Q4 operating profit and has announced a weaker-than-expected outlook.


The Danish group's Q4 operating profit came in at 17.09 billion Danish kronor, up 25% y-o-y, although below the consensus of 18.25 billion DKK.

Revenue was 48.09 billion DKK, up 25% y-o-y, which actually beat the consensus of 47.26 billion DKK.

The company said that it is targeting growth in both revenue and operating profit this year, up 9% to 14% in local currency.

At constant exchange rates, growth is expected between 13% and 19%, again below the consensus forecast.



Copyright (c) 2023 CercleFinance.com. All rights reserved.